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A B S T R A C T
Background
Pulmonary arteriovenous malformations are abnormal direct connections between the pulmonary artery and pulmonary vein which
result in a right-to-left shunt. They are associated with substantial morbidity and mortality mainly from the effects of paradoxical
emboli. Potential complications include stroke, cerebral abscess, pulmonary haemorrhage and hypoxaemia. Embolisation therapy is a
form of treatment based on the occlusion of the feeding arteries to a pulmonary arteriovenous malformation and can prevent many of
these debilitating and life-threatening complications.
Objectives
To determine the efficacy and safety of embolisation therapy in people with pulmonary arteriovenous malformations including a
comparison with surgical resection and different embolisation devices.
Search methods
We searched the Cystic Fibrosis and Genetic Disorders Group’s Trials Registers (last searched 07 September 2009). We also searched
the following databases: the Australian New Zealand Clinical Trials Registry; ClinicalTrials.gov; International Standard Randomised
Controlled Trial Number Register; International Clinical Trials Registry Platform Search Portal (last searched 22 November 2009). We
checked cross-references and searched references from review articles. Finally, we contacted manufacturers and specialised centres for
unpublished and ongoing trials.
Selection criteria
Trials in which individuals with pulmonary arteriovenous malformations were randomly allocated to embolisation therapy compared
to no treatment, surgical resection or a different embolisation device. Studies identified for potential inclusion were independently
assessed for eligibility by two authors, with excluded studies further checked by a third author.
Data collection and analysis
No trials were identified. As this was the case, no analysis was performed.
Main results
There were no randomised controlled trials identified.
1Embolisation therapy for pulmonary arteriovenous malformations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
Currently there are no randomised controlled trials to support or refute embolisation therapy for treatment of pulmonary arteriovenous
malformations. However, randomised controlled trials are not always feasible on ethical grounds. Observational studies suggest that
embolisation therapy reduces mortality and morbidity compared to no treatment in patients. A standardised approach to reporting
with long-term follow up through registry studies can help to strengthen the evidence base for embolisation therapy in the absence of
randomised controlled trials. Future viable randomised controlled trials may compare different embolisation devices against each other.
P L A I N L A N G U A G E S U M M A R Y
Embolisation therapy for pulmonary arteriovenous malformations
A pulmonary arteriovenous malformation is an abnormal connection between arteries and veins in the lung. It is known to cause serious
complications such as stroke, brain abscess, bleeding in the lungs and exercise intolerance. Embolisation therapy is the mainstream
treatment for pulmonary arteriovenous malformations. This comprises insertion of a catheter via the groin and eventual deployment of
balloon, coil, or combinations of balloon and coil devices to occlude the pulmonary arteriovenous malformation. However, these pul-
monary arteriovenous malformations can often be very small and be associated with multiple pulmonary arteriovenous malformations
in other parts of the lungs. This means they are not amenable to either embolisation or surgery. In this systematic review of the literature,
we did not identify any randomised controlled trials to support the use of embolisation treatments for pulmonary arteriovenous malfor-
mations. Neither did we find any comparison between embolisation therapy and surgery for pulmonary arteriovenous malformations.
In view of the known benefits of embolisation, trials comparing embolisation to no treatment or to surgery are considered unethical.
A more feasible study for future consideration will be to compare different embolisation devices. Currently, observational studies will
require a standardised approach to reporting as well as long-term follow up through registry studies to strengthen the evidence base for
embolisation therapy.
B A C K G R O U N D
Description of the condition
Pulmonary arteriovenous malformation (PAVM) is an abnormal
direct connection between a pulmonary artery and a pulmonary
vein. The malformations can manifest as a single focal lesion or as
multiple lesions. It is estimated that about 90% of individuals with
PAVMs have hereditary haemorrhagic telangiectasia (HHT) and
only about 50% of individuals with HHT have PAVMs (Cottin
2004; Shovlin 2008a). Therefore, individuals with PAVMs who
have not been previously diagnosed with HHT should be tested
for the genetic disorder (Shovlin 2008a). The incidence of PAVM
is 1 per 100 000 population with a male to female ratio ranging
from 1:1.5 to 1.8 (Abdalla 2006; Khurshid 2002). A large propor-
tion (83%) of PAVMs involves the lower lung zones, with involve-
ment of upper lung zones seen in 17%of individuals (Remy-Jardin
2006). A smaller subset of individuals with PAVMs has a more
severe and diffuse pattern of disease which is defined as PAVMs
involving every segmental or every subsegmental artery of at least
one lobe or most recently re-defined as PAVM involvement of
a single segmental artery rather than a whole lobe (Faughnan
2000; Pierucci 2008). The distribution of diffuse PAVM is more
commonly bilateral (72%) rather than unilateral (28%) (Pierucci
2008). APAVMis also described as being either simple or complex.
A simple PAVM is supplied by one artery, whereas the complex va-
riety receives blood supply from two or more arteries. Non HHT-
related PAVMs are most commonly sporadic, or secondary to
hepato-pulmonary syndrome, caval pulmonary shunts, or trauma
(Shovlin 2010).
The recognised features of HHT are all due to abnormalities of
vascular structure. Individuals with HHT have a tendency to form
blood vessels without intervening capillaries between an artery
and a vein. The connection segment between an artery and a
vein tends to be fragile and can rupture and bleed. The affected
small blood vessel is termed telangiectasia and the affected larger
blood vessel is termed arteriovenous malformation (AVM). Such
malformations in HHT are only occasionally congenital; most
develop during puberty. In 1999, the Scientific Advisory Board
of the HHT Foundation International Incorporated established
clinical criteria for the diagnosis of HHT known as the Curaςao
criteria (Shovlin 2000). Diagnosis of HHT is definite if three
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criteria are present. A diagnosis of HHT cannot be established in
people with only two criteria; however, a high index of clinical
suspicion should be maintained. A diagnosis of HHT is unlikely
if fewer than two criteria are present. The Curaςao criteria are as
follows:
1. epistaxis - spontaneous, recurrent nosebleeds;
2. telangiectases - at characteristic sites (lips, oral cavity,
fingers, nose);
3. visceral lesions - such as gastrointestinal telangiectasia (with
or without bleeding), pulmonary AVM, hepatic AVM, cerebral
AVM, spinal AVM;
4. family history - a first-degree relative with HHT.
Most people with PAVMs are identified as having HHT if it is
screened for carefully (Bayrak-Toydemir 2004). It is an autosomal
dominant disorder caused by a mutation in one of at least several
genes. Three gene mutations have been identified to date: HHT
type 1 results from gene mutations encoding endoglin and HHT
type 2 from gene mutations encoding ALK-1 (activin receptor-
like kinase1) (Abdalla 2006). A subset of people withHHT is asso-
ciated with juvenile polyposis harbour mutations in the SMAD4
gene (Abdalla 2006). There are at least two further unidentified
genes that can cause classical HHT (Govani 2009). The abnormal
vascular structure in HHT is in part due to an initiating event
combined with abnormal repair from an imbalance in TGF-β re-
lated functions (Shovlin 1999).
Description of the intervention
Currently, percutaneous embolisation therapy is the most com-
monly used treatment for people with PAVMs. The advantages of
embolisation therapy over surgical intervention of PAVMs are that
it is less invasive and easy to repeat. The three major indications
for treatment include:
1. prevention of neurological complications including stroke
and cerebral abscess (Shovlin 2008a);
2. improvement in exercise tolerance (Gupta 2002);
3. prevention of lung haemorrhage.
The radiological literature currently advocates embolisation ther-
apy to be offered to both symptomatic patients and asymptomatic
patients with PAVMs of a size amenable to embolisation. In the
past, some institutions considered PAVMs of 3 mm as a thresh-
old for embolisation; however, such recommendations were with-
drawn in 2006 with suggestions that smaller PAVMs may bene-
fit from embolisation. Treatment of PAVMs less than 3 mm in
size has the benefit of protection against bacterial embolisation
as well as paradoxic bland embolisation (Pollak 2006). Moreover,
smaller PAVMs have the potential to enlarge over time (Pollak
2006; Shovlin 2008a). However, embolisation of smaller vessels is
technically difficult because they are harder to cannulate, and this
may result in occlusion of larger proximal vessels.
The embolisation procedure is performed by an interventional ra-
diologist. There are variations in practice regarding the use of an-
tibiotic prophylaxis before catheter-directed embolisation, which
has the potential to produce bacteraemia (Borrero 2006; Shovlin
2008a). A right femoral venous puncture is used and a catheter is
directed into the right and then left pulmonary arteries. The initial
angiograms of each side provide a general overview of the number
and distribution of PAVMs. During embolisation of PAVM, the
target is the supplying artery immediately preceding the aneurys-
mal sac. The use of coaxial catheters allows precise placement of
the embolisation device and is critical to the outcome of the pro-
cedure (White 2007). In the co-axial catheter, the outer or guide
catheter, is essential for stable placement while the inner catheter
is used for deployment of embolisation device. Once the emboli-
sation device is securely in place, angiography is repeated to de-
termine whether all possible conduits to the aneurysmal sac have
been occluded.
How the intervention might work
The choice of embolisation device depends on the vascular
anatomy of the individual. In general, PAVMs with feeding artery
diameters of 3 to 9 mm are treated with either balloons or coils
and those with feeding artery diameters greater than 8 mm are
treated with coils alone or with an over-inflated balloon impacted
within a nest of coils (Lee 1997; Saluja 1999).
Types of embolisation device:
1. coil (various types of fibered and unfibered, detachable, and
pushable coils);
2. detachable balloon;
3. amplatzer vascular plugs, most recent device (Ferro 2007)
The deployed coils are designed to coil within the vessel lumen
and carry microfibres which activate platelets to generate an oc-
cluding platelet plug, while amplatzer and balloon devices provide
direct obstruction to vascular flow. Balloon embolisation offers an
additional advantage in that balloon inflation, placement, and lo-
cation may be adjusted before detachment of the device (Borrero
2006).The most recent embolisation device on the market is the
amplatzer vascular plug. This self-expanding cylindrical mesh cage
allows a chance of recapture and redeployment until proper posi-
tioning is achieved (Ferro 2007). The choice of embolisation de-
vice is operator-dependent and correct angiographic assessment
of vessel size can prevent device-associated complications such as
down-stream migration of the device.
Since embolisation became standard practice in the 1980s, surgi-
cal resection of PAVMs has largely been reserved for PAVMs not
amenable to embolisation. Surgery is also used as an emergency
procedure to control haemorrhage, when loss of lung tissue is justi-
fied. Available surgical techniques include different extent of surgi-
cal excision of PAVMs: local excision; segmental resection; lobec-
tomy; ligation; and even pneumonectomy, but whenever possible
lung conservation resection is the preferred choice of treatment.
It is important to emphasise that the majority of individuals with
PAVMs do not have disease suitable for surgery because the size
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and diffuse distribution of PAVMs. Chest computed tomography
(CT) studies indicate that fewer than one third of patients have
single PAVMs, and at least 60% to 70% have residual PAVMs too
small for embolization (Shovlin 2010). Hence any study compar-
ing surgical resection of PAVMs with embolisation will be feasible
only in a small selective portion of people with solitary PAVM and
without evidence of PAVMs elsewhere.
Neither embolisation therapy nor surgery will completely eradi-
cate PAVMs in people with HHT, as small PAVMs may persist
and new PAVMs may be formed. On the other hand, shunting
can be abolished even in people with HHT if large PAVMs are
treated. The majority of patients have small shunts. Hence, the
use of antibiotic prophylaxis in interventional procedures such as
embolisation therapy and dental procedures is still recommended
(Borrero 2006; Shovlin 2008a). Embolisation therapy and surgery
for PAVMs both require specialised techniques and experience.
Procedure complications are operator-dependent and are related
to the number of procedures performed annually (Hannan 1989).
Since HHT is a multi-organ disease, it is best managed in spe-
cialised HHT centres with high-volume experience as well as ac-
cess to multidisciplinary experts.
Why it is important to do this review
Although the natural history of untreated PAVMs has not been
optimally defined, data from observational studies of untreated
PAVM cases show considerable morbidity including stroke, cere-
bral abscess, hypoxaemia and haemorrhage (Faughnan 2000;
Pollak 2006). Mortality is considered to be caused by PAVM if
death is due to cerebral abscess, stroke, haemoptysis or haemotho-
rax. A study on the prevalence and mortality of HHT in a Danish
population found increased mortality, most pronounced amongst
those below the age of 60 years, with severe gastrointestinal bleed-
ing and history of untreated PAVM causing respiratory symptoms
as contributor to death (Kjeldsen 1999). A life-expectancy study
by Sabbà of 70 people with HHT also showed a decrease in aver-
age lifespan of HHT patients compared to a control group, with
a reduction of life expectancy approaching 6.8 years. A double
peak for mortality was observed with an early peak in the under-
50s and a late peak in the 60 to 79 year age group, which can
be attributed to major acute complications and chronic organ in-
volvement (Sabbà 2006). The study also highlighted the potential
for maternal complications with the deaths of two young women
during childbirth, due to haemorrhage from PAVMs and cere-
bral AVMs (Sabbà 2006). A cohort study by Shovlin provides the
first quantification of maternal complications of pregnancy in 111
women with HHT and PAVMs. The study showed that 1.0%
of pregnancies resulted in a major PAVM bleed; 1.2% in stroke
(not all were HHT-related); and 1.0% in maternal death (Shovlin
2008c).
The current practice recommends embolisation of all PAVMs in
the absence of contraindications such as severe pulmonary hyper-
tension, renal failure, and early pregnancy. In 2008, a cohort study
by Shovlin concluded that it is difficult to predict which HHT pa-
tients are at risk of PAVM complications with reference to PAVM
size, severity and symptoms (Shovlin 2008a). The study suggested
the need for greater emphasis onHHTdiagnosis, PAVMscreening
and the necessity of implementing PAVM treatment programmes
(Shovlin 2008a). This systematic review will provide an overview
of the available evidence from the literature and will show the
strength of evidence available in order to make recommendations
for current practice and future research.
O B J E C T I V E S
To establish if embolisation therapy is a safe and effective pro-
cedure for pulmonary arteriovenous malformations compared to
no intervention, as well as a comparison of different embolisation
devices. We also plan to include RCTs which compare surgical
resection of PAVMs with embolisation. This will be feasible in a
small selective portion of patients with single PAVM and without
evidence of PAVMs elsewhere.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials.
Types of participants
Participants of all ages with PAVMs with feeding arteries that are
determined to be suitable for embolisation therapy. Individuals
with both simple and complex PAVMs will be included in the
review.
Types of interventions
Embolisation techniques compared to no treatment or compari-
son of two different embolisation devices. Comparision of emboli-
sation to surgical resection of PAVMs will be included as emer-
gency procedure.
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Types of outcome measures
Primary outcomes
1. Initial occlusion as determined by angiogram immediately
after embolisation
2. Long-term occlusion as determined by
i) chest radiography (standard posteroanterior and lateral
chest radiographs)
ii) contrast “bubble” echocardiography
iii) radionuclide shunt study and pulse oximetry (SaO2)
a) measured in up-right position
b) measured in supine position
iv) computed tomography (CT)
a) high resolution CT (HRCT)
b) helical CT without contrast media
3. All causes mortality secondary to PAVM if death was due to
any cause, including:
i) cerebral abscess
ii) stroke
iii) haemoptysis
iv) haemothorax
Secondary outcomes
1. Exercise capacity (comparison with data obtained prior to
embolisation)
i) any recognised and reproducible exercise test e.g. 6-
minutes walk test
2. Pulmonary function tests (comparison with data prior to
embolisation)
i) forced expiratory volume in one second (FEV1)
ii) vital capacity
iii) single-breath diffusing capacity for carbon monoxide
(D LCO )
iv) diffusing capacity for carbon monoxide per unit of
alveolar volume (KCO[DL/VA]
3. Adverse events
i) device-related complications (e.g. vascular perforation,
intramural arterial dissection, myocardial rupture, device
migration, early deflation of balloon, and paradoxical balloon or
coil embolisation at the time of deployment)
ii) procedure-related complications (e.g. pulmonary
infarction, pulmonary hypertension, cardiac arrhythmias,
thrombophlebitis and deep venous thrombosis and those related
to the venous puncture, such as a haematoma, transient
symptoms (angina, confusion, bradycardia, and perioral
paraesthesias), transient ischaemic attacks and cerebrovascular
accident
Search methods for identification of studies
Electronic searches
Using the term ’hereditary haemorrhagic telangiectasia’, we
searched for relevant trials from the Cystic Fibrosis and Ge-
netic Disorders Group’s Trials Registers, compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated with each new issue of The Cochrane Li-
brary), and quarterly searches of MEDLINE. For details of hand
searching, please see the appropriate sections of the Cystic Fibrosis
and Genetic Disorders Group’s Module.
Latest search of the Group’s Trials Register: 07 September 2009,
searched for all years without limitations.
The search strategies forThe Cochrane Library andMEDLINE are
presented in Appendix 1 and Appendix 2 respectively. Date of the
last search of these databases: 07 September 2009.
We also searched the international registers of clinical trials
in the following databases for all years without limitations.
Searched terms used “pulmonary arteriovenous malformation(s)”
or “PAVM(s)”.
Latest search date: 22 November 2009.
• Australian and New Zealand Clinical Trials Registry;
• Clinicaltrials.gov;
• International Standard Randomised Controlled Trial
Number Register;
• International Clinical Trials Registry Platform Search
Portal.
Searching other resources
We contacted medical equipment manufacturers of embolisation
devices by email, to identify any unpublished trials.
• Cook Medical (contacted 14 November 2009).
• AGA Medical Cooporation, manufacturers of Amplatzer
Vascular Plug (contacted 14 November 2009).
We contacted the specialised HHT Centers listed by the Osler-
Weber-Rendu-HHTFoundation International by email for results
of unpublished clinical studies.
We also scrutinised references of papers identified in the above
searches and also references used in this review for possible pub-
lished articles.
Data collection and analysis
Since no trials were included in the review, we are unable to carry
out any analysis. For future updates, when studies are identified
for inclusion in the review, the following methods will be applied.
Selection of studies
Two authors (CC-THandGNCK) independently assessed studies
identified for inclusion in the reviewusing the criteria stated above.
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When there were disagreements, the third author (SAT) acted as
arbiter.
Data extraction and management
Two authors (CC-TH and GNCK) will independently extract
data from the studies included in the review using a standard data
extraction form. If there are disagreements, the third author (SAT)
will act as arbiter. We will assess outcome measures at time in-
tervals as follows: primary outcomes concerning long-term occlu-
sions, adverse events; and all secondary outcomes measures will
be assessed at intervals up to three months, up to six months, up
to one year and annually thereafter. If different time points are
reported we will also consider these.
Assessment of risk of bias in included studies
The authors (CC-TH, GNCK and MLvD) will assess the risk of
bias for each study as described in the Cochrane Handbook for
Systematic Reviews of Interventions 5.0 (Higgins 2009) for each
of the following domains:
1. randomisation
2. allocation concealment
3. blinding (of participants, personnel and outcome assessors)
4. completeness of data
5. selective outcome reporting
6. other sources of bias
Measures of treatment effect
When dealing with dichotomous outcome measures, we will cal-
culate a pooled estimate of the treatment effect for each outcome
across trials using the odds ratio (OR) (the odds of an outcome
among treatment allocated participants to the corresponding odds
among controls) and the 95% confidence intervals (CIs). For con-
tinuous outcomes, we plan to record either mean change from
baseline for each group or mean post-intervention values and stan-
dard deviation for each group. Then, where appropriate, we plan
to calculate a pooled estimate of treatment effect by calculating
the mean difference and 95% CIs.
Unit of analysis issues
Cross-over trials are not included in the review because there is
only a single treatment designated to each group. If treatment by
embolisation is successful, it is inappropriate to expose participants
to other forms of intervention, i.e. surgery.
Dealing with missing data
In order to allow an intention-to-treat analysis, we plan to seek
data on the number of participants with each outcome event by
allocated treatment group, irrespective of compliance and whether
or not the participantwas later thought to be ineligible or otherwise
excluded from the treatment or follow up. The review authors
will request any missing data from the original investigators if
appropriate.
Assessment of heterogeneity
We plan to assess statistical heterogeneity in the meta-analysis us-
ing the I2 statistic (Higgins 2009) and explore reasons for hetero-
geneity. Thresholds for the interpretation of I2 can be misleading,
since the importance of inconsistency depends on several factors.
We plan to use the rough guide to interpretation as outlined in
the Handbook (Higgins 2009).
Assessment of reporting biases
We will investigate publication bias using funnel plots if 10 or
more studies are identified.
Data synthesis
We plan to use a fixed-effect model in our analysis. If we identify
heterogeneity (I2 greater than 50%), we will assess the significance
of the treatment effect by using a random-effects model.
Subgroup analysis and investigation of heterogeneity
We plan the following subgroup analyses if 10 or more studies are
identified, with participants stratified by the following factors:
1. embolisation materials
i) coil (various types of fibered and unfibered,
detachable, and pushable coils)
ii) detachable balloon embolisation
iii) amplatzer vascular plugs
2. emergency treatments of PAVMs: surgical resection versus
embolisation
3. simple versus complex PAVMs
4. children (up to 18 years) versus adults (18 years and over)
Sensitivity analysis
We plan to undertake sensitivity analysis where only trials with
adequate allocation concealment and blinding are included.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
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Results of the search
The search of the Cystic Fibrosis and Genetic Disorders Review
Group’s Trials Registers did not identify any relevant trials. There
were also no trials identified from searches of the ongoing trials
databases.
The search of The Cochrane Library did not identify any trials rel-
evant to the topic. The MEDLINE searches yield did not iden-
tify any RCTs, however, eight observational studies relevant to the
topic were classified as excluded studies. Cross-referencing failed
to identified any RCTs; 17 observational studies relevant to the
topic were identified. This includes 8 prospective case series listed
in Characteristics of excluded studies and 17 retrospective case
reviews included in the Additional references.
We contacted the following medical equipment manufacturers of
embolisation devices by email, to identify any unpublished trials,
but have not yet received a response:
• Cook Medical (contacted 14 November 2009);
• AGA Medical Cooporation, manufacturers of Amplatzer
Vascular Plug (contacted 14 November 2009).
We contacted the specialised HHT Centers listed by the Osler-
Weber-Rendu-HHTFoundation International by email for results
of unpublished clinical studies. Twelve centres responded, with no
RCTs identified.
• HHT Center Israel Schneider Children’s Medical Center of
Israel Rabin Medical Center, Tel Aviv University (replied 14
December 2009): no RCTs identified.
• HHT Center Norway, Rikshospitalet University Hospital
(replied 9 December 2009): no RCTs identified.
• The Institute of Vascular Interventional Radiology, The
First Affiliated Hospital of China Medical University (replied 8
December 2009): no RCTs identified.
• National HHT Centre Ireland, Mercy University Hospital
(replied 6 December 2009): no RCTs identified.
• HHT Center Spain, Hospital Sierrallana (Servicio Cantabro
de Salud) (replied 4 December 2009): no RCTs identified.
• HHT Germany-Marburg, Philipps-University (replied 4
December 2009): no RCTs identified.
• HHT Germany-Cologne, Holweide Hospital (replied 2
December 2009): no RCTs identified.
• HHT Germany-Lippspringe, Karl-Hansen Medical Center
(replied 2 December 2009): no RCTs identified.
• HHT London, Hammersmith Hospital (replied 27
November 2009): no RCTs identified.
• Edmonton HHT Center (replied 25 November 2009): no
RCTs identified.
• Washington University School of Medicine (replied 22
November 2009): no RCTs identified.
• Medical College of Georgia HHT Center (replied 19
November 2009): no RCTs identified
Included studies
No randomised controlled trials have been identified which are
eligible for inclusion in the review.
Excluded studies
The studies listed as ’Excluded studies’ were not eligible for inclu-
sion because they were neither randomised and quasi-randomised
controlled trials (Dutton 1995; Gupta 2002; Haitjema 1995;
Lacombe 2009; Pollak 1994; Pollak 2006; Shovlin 2008a; Shovlin
2008b). See Characteristics of excluded studies.
Seventeen studies were retrospective case reviews which we did
not feel should be listed as ’Excluded studies’, but we have listed
these in the Additional references section for completeness (Brillet
2007; Cil 2008; Curie 2007; Faughnan 2000; Faughnan 2004; Lee
1997; Mager 2004; Pierucci 2008; Post 2006; Prasad 2004; Remy
1992; Remy-Jardin 2006; Sagara 1998; Saluja 1999; Swanson
1999; White 1983; White 1988).
Risk of bias in included studies
There are no included studies.
Effects of interventions
Noeligible studies for inclusion in this reviewhave been identified.
D I S C U S S I O N
Pulmonary arteriovenousmalformation (PAVM) can cause serious
neurologic complications (stroke, cerebral abscess), pulmonary
haemorrhage and hypoxaemia. The prognosis from historical un-
treated individuals suggests substantial mortality and morbidity.
Overall, approximately 33% of individuals with PAVM will have
a history of stroke, 18% of transient ischaemic attack (TIA), 23%
of cerebral abscess, 3% of haemothorax and 59% with symptoms
of dyspnoea or exercise intolerance (Pollak 2006). Embolisation
therapy has become mainstream treatment for PAVMs since it was
introduced in the 1980s. It is less invasive andmay reduce the risks
associated with the original standard surgical treatment. Despite
this, we did not find any evidence from RCTs or CCTs assessing
the role of embolisation in the management of PAVMs. We ex-
cluded 25 observational studies, including 8 prospective case series
(listed in Characteristics of excluded studies) and 17 retrospective
case reviews (included in the Additional references).
A retrospective study by Remy-Jardin evaluated the long-term ef-
fectiveness of coil embolisation therapy (38 individuals with 64
PAVMs) over approximately 10 years (Remy-Jardin 2006). Follow
up with CT imaging showed a long-term success rate of 75%;
treatment failure was attributed to recanalisation of the occluded
7Embolisation therapy for pulmonary arteriovenous malformations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
feeding artery, previously unrecognised additional feeding arteries
of complex PAVMs and development of systemic perfusion of the
aneurysmal sac (Remy-Jardin 2006). A prospective study by Pol-
lack using embolisation (415 PAVMs in 155 individuals) empha-
sised the need for both clinical follow up and imaging evaluation
after embolization therapy when problems related to PAVMs oc-
curred in 23% of individuals and residual lesions were detected
by CT imaging in 2.8% of patients. In addition, CT detected en-
largement of previous small PAVMs in 18% of individuals, many
of whom were asymptomatic (Pollak 2006).
A prospective study by Shovlin (323 individuals with HHT and
PAVMs, median age 45 years) provides the strongest evidence to
date showing a significant reduction in the rate of ischaemic stroke
following embolisation. However, strokes and brain abscesses oc-
curred in some individuals with small untreatable PAVMs de-
spite other existing PAVMs having been treated by embolisation
(Shovlin 2008a). The benefits of embolisation therapy also ex-
tended to those with diffuse pattern of disease with two retrospec-
tive reviews suggesting reduction of neurological complications
after successful embolisation in most patients (Faughnan 2000;
Lacombe 2009). The post-embolisation morbidity and mortality
can also be attributed to reperfusion of embolised PAVMs or en-
largement of non-embolised PAVMs (Lacombe 2009).
Complications (such as cerebral infarction, chest pain or device-
related complications) resulting from embolisation therapy in the
excluded observational studies appear to be limited (Lee 1997;
Mager 2004; Pollak 2006). A retrospective study showed that em-
bolisation of PAVMs did not lead to a consistent increase in rest-
ing pulmonary artery pressure in a series which excluded individu-
als with severe pulmonary arterial hypertension (Shovlin 2008b).
In rare cases, massive haemoptysis has been reported at follow-
up post embolisation (Sagara 1998; Pierucci 2008). These can be
attributed to the development of bronchial feeding arteries to em-
bolised PAVM.
Evidence suggests that PAVM can occur early in life and present
with serious life-threatening complications; however, there are
currently only a limited number of observational studies avail-
able on embolisation therapy for PAVM in children (Curie 2007;
Faughnan 2004). There is only limited evidence from observa-
tional studies that children can benefit from embolisation therapy
with success and complication rates comparable to adults.
To date no experimental studies (i.e. RCTs) have supported the
fact that embolisation therapy has become mainstream treatment
for PAVMs. Information on the effectiveness of the procedure and
procedure-related complications is only available from non-con-
trolled, mostly retrospective observational case series.These stud-
ies have a high risk of bias, e.g. a biased selection of participants,
recall bias due to poor reporting in medical records, and ascertain-
ment bias (Higgins 2009). Evidence from observational data only
without any comparison to a control group cannot determine if
embolisation therapy is the most effective treatment for PAVM.
However, given the fact that exposing patients to potentially more
harmful procedures (i.e. surgical removal of the PAVM) in a RCT
would be undesirable for ethical reasons, it is unlikely that high-
level evidence will become available in the near future. In order to
strengthen the evidence base for embolisation therapy, a standard-
ised approach to reporting patient characteristics, co-morbidity
(and any other potential confounders) and procedures, as well as
long-term follow up protocols are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the 1980s clinical practice moved away from surgical treatment
of PAVMs to embolisation as the latter is less invasive, avoids
risks associated with general anaesthesia and minimises the loss
of pulmonary parenchyma. We have not identified any evidence
from RCTs supporting embolisation therapy in the treatment of
PAVMs. We also have not identified any RCTs that compare em-
bolisation therapy with surgical resection of PAVM. The current
evidence for embolisation therapy is based on observational stud-
ies, mainly retrospective case series and some prospective studies.
These observational studies suggest embolisation results in sub-
stantial reductions inmortality and morbidity. The procedure and
device complication rates have been minimal; however, serious
complications include precipitation of pulmonary hypertension
and massive haemoptysis. These recommendations suggest that
all PAVMs should be treated with embolisation therapy and that
surgery is to be reserved for individuals with PAVMs that are not
amenable to embolisation or have other contraindications to em-
bolisation, such as an allergy to contrast material. It is important
to note that whilst individuals may have lesion(s) suitable for em-
bolisation, the majority will also have diffuse disease or PAVMs
too small for any procedure.
Implications for research
There is a need for stronger evidence to support the clinical prac-
tice of embolisation therapy for PAVMs. However, RCTs are not
always feasible on ethical grounds as accumulated evidence from
observational studies suggests that embolisation results in substan-
tial reductions in mortality and morbidity. An RCT comparing
embolisation to surgery may only be feasible in a selective small
proportion of patients with an apparent single PAVM and with-
out evidence of disease elsewhere. However, future RCTs should
compare different embolisation devices.
In the absence of RCTs, we suggest a standardised approach to
reporting, as well as long-term follow up through registry studies
to help determine the safety and outcome of embolisation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dutton 1995 Prospective case series of 53 participants with PAVMs treated with coil embolisation
Gupta 2002 Prospective case series of 66 consecutive individuals, 225 PAVMs were occluded by coil embolisation
Haitjema 1995 Prospective case series of 32 individuals, 92 PAVMs were treated by coil embolisation
Lacombe 2009 Prospective case series of 39 individuals previously identified to have bilateral PAVM. 681 PAVMs were occluded
by embolisation therapy. 238 PAVMs were treated using the peripheral blood flow redistribution technique
Pollak 1994 Prospective study of 35 individuals, 96 PAVMs, underwent embolisation with detachable silicone balloon, coil or
combination
Pollak 2006 Prospective study of 155 individuals, 415 PAVMs underwent embolisation with balloon, coil or combination of
both
Shovlin 2008a Prospective study of 323 consecutive individuals with PAVMs (n = 219) and/or HHT (n = 305) was performed.
Anderson-Gill models assessed constant and time dependent potential predictive variables for stroke/abscess, and
rate reduction by PAVM embolisation
Shovlin 2008b Prospective study of 143 individuals, 4 individuals were excluded from the study due to severe pulmonary hyper-
tension, underwent embolisation and measurement of pulmonary artery pressure
CT: computed tomography
HHT: hereditary haemorrhagic telangiectasia
PAVM: pulmonary arterial malformation
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search Strategy for the Cochrane Library
ID Search
#1 pulmonary near (arteriovenous malformation*)
#2 pulmonary near (arteriovenus fistula)
#3 pulmonary near avm
#4 pulmonary near (a-v malformation)
#5 pavm
#6 (#1 OR #2 OR #3 OR #4 OR #5)
Appendix 2. Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) 1948 to Present with Daily Update
Search Strategy:
#1 exp Arteriovenous Malformations/ 21933
#2 arteriovenous malformation$.mp. [mp=title, original title, ab-
stract, name of substance word, subject heading word]
13697
#3 arteriovenus fistula.mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
2
#4 avm.mp. [mp=title, original title, abstract, name of substance
word, subject heading word]
2494
#5 a-v malformation.mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
41
#6 4 or 1 or 3 or 2 or 5 23615
13Embolisation therapy for pulmonary arteriovenous malformations (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#7 pulmonary.mp. adj4 (avm.mp. or exp Arteriovenous Malfor-
mations/ or arteriovenus fistula.mp. or arteriovenous malfor-
mation$.mp. or a-v malformation.mp.) [mp=title, original ti-
tle, abstract, name of substance word, subject heading word]
2556
#8 PAVM.mp. [mp=title, original title, abstract, name of sub-
stance word, subject heading word]
145
#9 8 or 7 2565
#10 exp Embolization, Therapeutic/ 20416
#11 emboli#ation.mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
29651
#12 11 or 10 31188
#13 9 and 12 530
#14 randomized controlled trial.pt. 280487
#15 controlled clinical trial.pt. 80543
#16 randomized.ab. 189298
#17 placebo.ab. 115470
#18 drug therapy.fs. 1347511
#19 randomly.ab. 137122
#20 trial.ab. 196159
#21 groups.ab. 936463
#22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 2468635
#23 (animals not (humans and animals)).sh. 3350294
#24 22 not 23 2092778
#25 24 and 13 21
#26 from 25 keep 1-21 21
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